[
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-1",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#definitiongeneral474583",
    "clean_content": "Definition / general\n\n* ALK positive histiocytosis (APH) is a histiocytic neoplasm characterized by *ALK* (anaplastic lymphoma kinase) gene rearrangements and ALK immunoreactivity in the lesional histiocytes ([Leukemia 2022;36:1703](35732831), [Blood 2022;140:1229](35653592), [Blood 2022;139:256](34727172))* Initially described in 2008 presenting as systemic histiocytosis in infants ([Blood 2008;112:2965](18660380))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-2",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#essentialfeatures474584",
    "clean_content": "Essential features\n\n* Rare non-Langerhans cell histiocytic neoplasm with heterogeneous clinical features, presenting as single system disease, multisystem with systemic hematopoietic involvement (liver, spleen or marrow, skin, central nervous system [CNS]) or other multisystem disease (tumorous involvement of ≥ 2 organ systems)* ALK expression by immunohistochemistry, predominantly in a cytoplasmic pattern, rarely in a membranous or Golgi (dot-like) pattern and practically never in a nuclear pattern* Cytoplasmic ALK expression by immunohistochemistry with coexpression of histiocytic markers (CD68, CD163, CD4) is crucial to distinguish this entity from other histiocytic or spindle cell morphologic mimics* Characteristic *ALK* gene rearrangements allow for targeted therapy with ALK inhibitors"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-3",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#terminology474585",
    "clean_content": "Terminology\n\n* ALK related histiocytosis* *ALK* rearranged histiocytosis"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-4",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#icdcoding474586",
    "clean_content": "ICD coding\n\n* ICD-10: [D76.3](https://www.icd10data.com/ICD10CM/Codes/D50-D89/D70-D77/D76-/D76.3) - other histiocytosis syndromes"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-5",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#epidemiology474587",
    "clean_content": "Epidemiology\n\n* Affects any age group, including children and young adults, with a female predilection ([Blood 2022;139:256](34727172))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-6",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#sites474588",
    "clean_content": "Sites\n\n* Multisystem with systemic hematopoietic involvement\n  + Systemic involvement of liver, spleen or bone marrow with or without involvement of additional sites ([Blood 2022;139:256](34727172), [Leukemia 2022;36:1720](35732829))* Multisystem disease, others\n    + ≥ 2 organs, most commonly central and peripheral nervous system, bone, lung and skin ([Leukemia 2022;36:1720](35732829), [Blood 2022;139:256](34727172))* Single system disease\n      + Tumorous involvement of a single organ with solitary or multiple lesions+ Most common sites include central and peripheral nervous system, skin, soft tissue and breast ([Blood 2022;139:256](34727172))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-7",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#pathophysiology474589",
    "clean_content": "Pathophysiology\n\n* Fusion of the receptor tyrosine kinase domain of the *ALK* gene, most commonly to exon 24 of *KIF5B*, results in constitutive activation of downstream signaling, including RAS-RAF-MEK-ERK (MAPK) and PI3K / AKT / mTOR signaling pathways* MAPK pathway activation leads to phosphorylation of downstream ERK, ultimately resulting in transcription of various effector genes, including the gene encoding for cyclin D1 (*CCND1*); translation of *CCND1* messenger RNA to the cyclin D1 protein is mTOR dependent ([Blood 2022;139:256](34727172))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-8",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#etiology474590",
    "clean_content": "Etiology\n\n* Unknown at this time"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-9",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Diagrams / tables",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#diagramstables474591",
    "clean_content": "Diagrams / tables\n\n*Images hosted on other servers:*  \n\n[![Reported sites of involvement](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisnih01.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759533/figure/F6/)\n\nReported sites of involvement"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-10",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#clinicalfeatures474592",
    "clean_content": "Clinical features\n\n* Diverse clinical presentations depending on site(s) of involvement* Infants with multisystem disease involving the hematopoietic system present with hepatomegaly, anemia and thrombocytopenia, often accompanied by splenomegaly and coagulopathy* Other multisystem and single system disease presents with varying mass effects depending on tumor size and location ([Blood 2022;139:256](34727172))\n      + Neurologic involvement may present with headache, nausea / vomiting, ataxia, paresis, seizure, diplopia or trigeminal neuralgia+ Pulmonary involvement may present with dry cough or respiratory dysfunction requiring oxygen therapy+ Liver involvement may present with jaundice, coagulopathy or fever+ Cutaneous lesions present as slowly growing papules or nodules"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-11",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#diagnosis474593",
    "clean_content": "Diagnosis\n\n* Comprehensive patient evaluation including clinical history, physical examination and imaging studies* Coexpression of histiocytic markers and ALK should prompt molecular confirmation of *ALK* gene rearrangement either by RNA sequencing or by FISH (fluorescence in situ hybridization) analysis* References: [Mod Pathol 2019;32:598](30573850), [Blood 2022;139:256](34727172)"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-12",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#laboratory474594",
    "clean_content": "Laboratory\n\n* Variable, depending on organ system(s) involved* Liver involvement can be associated with elevated liver enzymes, elevated bilirubin and low fibrinogen ([Blood 2022;139:256](34727172))* Hematopoietic involvement can be associated with anemia, thrombocytopenia and prolonged prothrombin time and activated partial thromboplastin time ([Blood 2022;139:256](34727172))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-13",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#radiologydescription474595",
    "clean_content": "Radiology description\n\n* Mass lesions can be identified by ultrasound, Xray, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET) CT and other imaging modalities ([Blood 2022;139:256](34727172))\n  + Liver, pancreas, long bone lesions appear hypermetabolic on PET CT imaging+ Liver and thyroid lesions appear hypoechoic on ultrasound+ Kidney tumors appear hypodense on CT imaging+ Tumors of the vertebral bodies and liver appear hyperintense by T2 weighted MRI* CNS tumors rarely can mimic meningioma on MRI ([Radiol Case Rep 2023;18:2259](37123042))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-14",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#radiologyimages474596",
    "clean_content": "Radiology images\n\nContributed by Keri Janowiak, M.D., M.Ed.  \n\n[![Screening mammography](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak01.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak01.jpg)\n\nScreening mammography\n\n  \n  \n*Images hosted on other servers:*  \n\n[![Nonneurologic disease manifestations](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisnih02.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759533/figure/F3/)\n\nNonneurologic disease manifestations\n\n[![Left frontal lobe tumor](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisapm03.jpg)](https://apm.amegroups.org/article/view/78817/html#figure1)\n\nLeft frontal lobe tumor"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-15",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#prognosticfactors474597",
    "clean_content": "Prognostic factors\n\n* Prognosis depends on extent of disease and location(s) of tumor(s)* Typically favorable outcomes in cases with single system disease* Reports of death due to multisystem disease progression include every age group ([Mod Pathol 2019;32:598](30573850), [Blood 2022;139:256](34727172), [JCO Precis Oncol 2021;5:PO.20.00383](34036223))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-16",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#casereports474598",
    "clean_content": "Case reports\n\n* 17 month old boy with a 5.1 cm intracranial mass, multiple nodules in the liver and bilateral lungs, as well as multiple skin papules ([Orphanet J Rare Dis 2023;18:53](36915094))* 27 year old man with a 1.5 cm intradural extramedullary enhancing lesion ([Turk Patoloji Derg 2021;37:172](33973641))* 30 year old man with cavernous sinus lesion mimicking meningioma ([Radiol Case Rep 2023;18:2259](37123042))* 38 year old woman with multiple unilateral breast lesions ([Int J Surg Case Rep 2022;97:107435](35908452))* 50 year old woman with appendiceal nodule ([Haematologica 2019;104:e534](31371408))* 51 year old woman with lesions identified in the right lung, central nervous system and iliac lymph nodes ([Ann Palliat Med 2021;10:10095](34628929))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-17",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#treatment474599",
    "clean_content": "Treatment\n\n* Management varies depending on extent of disease and site(s) of involvement* Surgical resection is often definitive treatment for single system disease ([Blood 2022;139:256](34727172))* Systemic therapy for incompletely resected or unresectable tumors and for multisystem disease includes steroids, intravenous immune globulin (IVIG) or chemotherapy* Targeted therapy with ALK inhibitors has been used as first or second line treatment in a majority of cases ([Blood 2022;139:256](34727172), [JCO Precis Oncol 2021;5:PO.20.00383](34036223), [Oncologist 2017;22:1444](29079636))\n        + ALK inhibitors include alectinib, loratinib, brigatinib, crizotinib, ceritinib and entrectinib+ Used as monotherapy or in combination with other treatment modalities* Rare cases have resulted in spontaneous regression ([Blood 2022;139:256](34727172))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-18",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Clinical images",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#clinicalimages474600",
    "clean_content": "Clinical images\n\n*Images hosted on other servers:*  \n\n[![scalp lesion](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisnih04.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759533/figure/F5/)\n\nScalp lesion"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-19",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#grossdescription474601",
    "clean_content": "Gross description\n\n* Tumors may be well circumscribed or ill defined with a tan, white or yellow cut surface"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-20",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#grossimages474602",
    "clean_content": "Gross images\n\n*Images hosted on other servers:*  \n\n[![Breast APH lesion](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisnih06.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403183/figure/f0015/)\n\nBreast APH lesion\n\n[![Filum terminale](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisnih07.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512673/figure/F63165881/)\n\nFilum terminale"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-21",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#microscopichistologicdescription474603",
    "clean_content": "Microscopic (histologic) description\n\n* Large oval (epithelioid), foamy or spindle cells in varying proportions without significant nuclear atypia and abundant eosinophilic cytoplasm ([Mod Pathol 2019;32:598](30573850), [Blood 2022;139:256](34727172))* Large histiocytes may show irregular nuclear contours (indentation, folding, clefting, lobulation) with fine chromatin and small nucleoli ([Mod Pathol 2019;32:598](30573850), [Blood 2022;139:256](34727172))* Occasional multinucleated cells, including Touton giant cells, may be present ([Mod Pathol 2019;32:598](30573850), [Blood 2022;139:256](34727172))* Emperipolesis, characterized by engulfment of inflammatory cells (similar to Rosai-Dorfman disease), may be observed ([Mod Pathol 2019;32:598](30573850), [Blood 2022;139:256](34727172))* Hepatic involvement may show coalescing histiocytes indistinguishable from hepatocytes ([Mod Pathol 2019;32:598](30573850))* Bone marrow infiltration may vary from focal to extensive involvement ([Mod Pathol 2019;32:598](30573850))* Skin lesions are often noncircumscribed, nonepidermotropic infiltrates composed of sheets of histiocytes with varying degree of fibrosis ([Mod Pathol 2019;32:598](30573850))* Fascicular and storiform growth patterns common in breast tumors ([Am J Surg Pathol 2021;45:347](32826530))"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-22",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#microscopichistologicimages474604",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Keri Janowiak, M.D., M.Ed., Ekene Okoye, M.D. and Aishwarya Ravindran, M.D.  \n\n[![Storiform and fascicular growth](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak02.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak02.jpg)\n\nStoriform and fascicular growth\n\n[![Infiltrative growth](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak03.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak03.jpg)\n\nInfiltrative growth\n\n[![Histiocyte morphology](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak04.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak04.jpg)\n\nHistiocyte morphology\n\n[![Touton giant cells](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak05.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak05.jpg)\n\nTouton giant cells\n\n[![CD68](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak06.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak06.jpg)\n\nCD68\n\n  \n\n[![CD163](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisOkoye07.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisOkoye07.jpg)\n\nCD163\n\n[![Factor XIIIa](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisOkoye08.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisOkoye08.jpg)\n\nFactor XIIIa\n\n[![ALK](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisRavindran09.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisRavindran09.jpg)\n\nALK\n\n[![Cyclin D1](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisOkoye10.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisOkoye10.jpg)\n\nCyclin D1\n\n[![SMA](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak11.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesalkhistiocytosisJanowiak11.jpg)\n\nSMA"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-23",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Peripheral smear description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#peripheralsmeardescription474605",
    "clean_content": "Peripheral smear description\n\n* In systemic cases with hematopoietic involvement, anemia, thrombocytopenia and leukocytosis are usually seen"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-24",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#positivestains474606",
    "clean_content": "Positive stains\n\n* [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html)\n  + Cytoplasmic staining most common; occasionally membranous or dot-like Golgi pattern+ Lacks nuclear expression+ Can be weak or focal* [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD14](https://www.pathologyoutlines.com/topic/cdmarkerscd10to19.html#cd14), [CD4](https://www.pathologyoutlines.com/topic/cdmarkerscd4.html), [lysozyme](https://www.pathologyoutlines.com/topic/stainslysozyme.html)* [Factor XIIIa](https://www.pathologyoutlines.com/topic/stainsfactorxiiia.html), [fascin](https://www.pathologyoutlines.com/topic/stainsfascin.html), [cyclin D1](https://www.pathologyoutlines.com/topic/stainscyclind1.html) ([Am J Clin Pathol 2023;160:1](37167084))* Some cases show positivity for [S100](https://www.pathologyoutlines.com/topic/stainss100.html) and [OCT2](https://www.pathologyoutlines.com/topic/stainsOCT2.html), mimicking Rosai-Dorfman disease ([Blood 2008;112:2965](18660380), [Am J Clin Pathol 2023;160:1](37167084))* **pERK** expression as a consequence of MAPK pathway activation"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-25",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#negativestains474607",
    "clean_content": "Negative stains\n\n* [CD1a](https://www.pathologyoutlines.com/topic/cdmarkerscd1a.html), [langerin](https://www.pathologyoutlines.com/topic/cdmarkerscd200.html#cd207) ([Mod Pathol 2019;32:598](30573850), [Am J Surg Pathol 2021;45:347](32826530))* [CD23](https://www.pathologyoutlines.com/topic/cdmarkerscd23.html), [CD21](https://www.pathologyoutlines.com/topic/cdmarkerscd21.html)* [Keratin](https://www.pathologyoutlines.com/topic/stainsckgeneral.html)* [SMA](https://www.pathologyoutlines.com/topic/stainsalphasmoothmuscleactin.html), [desmin](https://www.pathologyoutlines.com/topic/stainsdesmin.html) (positivity seen in background stromal cells only) ([Am J Surg Pathol 2021;45:347](32826530))* [CD2](https://www.pathologyoutlines.com/topic/cdmarkerscd1.html#cd2), [CD3](https://www.pathologyoutlines.com/topic/cdmarkerscd3.html), [CD4](https://www.pathologyoutlines.com/topic/cdmarkerscd4.html), [CD5](https://www.pathologyoutlines.com/topic/cdmarkerscd5.html), [CD7](https://www.pathologyoutlines.com/topic/cdmarkerscd1.html#cd7), [CD20](https://www.pathologyoutlines.com/topic/cdmarkerscd20.html), [CD30](https://www.pathologyoutlines.com/topic/cdmarkerscd30.html) (positivity seen in background lymphocytes only)"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-26",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#molecularcytogeneticsdescription474608",
    "clean_content": "Molecular / cytogenetics description\n\n* *ALK* rearrangements detected by FISH* *ALK* fusion partners identified via targeted RNA sequencing ([Blood 2022;139:256](34727172))\n    + Most common: *KIF5B::ALK* fusion (~70 - 75% of cases)+ Other fusion partners reported: *CLTC*, *TPM3*, *TFG*, *EML4*, *DCTN1*, *TRIM33*, *COL1A2*"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-27",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Molecular / cytogenetics images",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#molecularcytogeneticsimages474609",
    "clean_content": "Molecular / cytogenetics images\n\n*Images hosted on other servers:*  \n\n[![ALK FISH, breakapart probe](https://www.pathologyoutlines.com/thumb/lymphnodesalkhistiocytosisnih05.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010018/figure/Fig1/)\n\n*ALK* FISH, breakapart probe"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-28",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#samplepathologyreport474610",
    "clean_content": "Sample pathology report\n\n* Left breast mass, lumpectomy:\n  + ALK positive histiocytosis, 9 mm in greatest dimension (see comment)+ Comment: Lesional histiocytes are characterized by cytoplasmic expression of ALK with coexpression of histiocytic markers (CD68, CD163) and cyclin D1. Molecular analysis by RNA sequencing was positive for *KIF5B::ALK* fusion. The overall immunophenotype in conjunction with the molecular analysis supports the above diagnosis."
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-29",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#differentialdiagnosis474611",
    "clean_content": "Differential diagnosis\n\n* **Reactive fibrohistiocytic proliferation**:\n  + Observed in infectious or inflammatory conditions as well as fat necrosis+ Emperipolesis may be present (not pathognomonic for histiocytic neoplasms)+ IHC negative for [S100](https://www.pathologyoutlines.com/topic/stainsS100.html), [OCT2](https://www.pathologyoutlines.com/topic/stainsOCT2.html) and [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html)+ Lacks *ALK* gene fusions* [Rosai-Dorfman disease (RDD)](https://www.pathologyoutlines.com/topic/lymphnodessinushistiocytosiswithmassivelymph.html):\n    + Parenchymal effacement of nodal / extranodal tissue by large histiocytes with round / oval nuclei, pale chromatin, distinct nucleoli and abundant pale cytoplasm with frequent engulfment of inflammatory cells (emperipolesis)+ Abundant plasma cells and small lymphocytes; occasionally, neutrophils may also be present+ By immunohistochemistry, positive for [S100](https://www.pathologyoutlines.com/topic/stainsS100.html), [OCT2](https://www.pathologyoutlines.com/topic/stainsOCT2.html); uniformly negative for [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html)+ ~10% of cases are negative for [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163) ([Am J Clin Pathol 2023;160:1](37167084))+ Lacks *ALK* gene fusions* [Juvenile xanthogranuloma (JXG)](https://www.pathologyoutlines.com/topic/skintumornonmelanocyticjuvenilexantho.html):\n      + Usually affects pediatric population with ~33% of cases presenting within the first year of life+ Predominantly cutaneous involvement presenting as papulonodular lesions and usually asymptomatic / self resolving over months / years+ < 5% may be systemic JXG, including CNS that may present as seizures, hydrocephalus, diabetes insipidus; bone marrow involvement presents with cytopenias+ Nonencapsulated circumscribed lesions composed of large xanthomatous (foamy) histiocytes with bland nuclear features and Touton giant cells; occasionally lesions may be composed of spindled, epithelioid or oncocytic histiocytes+ Typically has an inflammatory background with a mixed population of lymphocytes, eosinophils, plasma cells, neutrophils and mast cells+ IHC negative for [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html)+ Lacks *ALK* gene fusions* [Erdheim-Chester disease](https://www.pathologyoutlines.com/topic/boneerdheim.html):\n        + Heterogeneous clinical manifestations, most commonly presenting with bone pain, secondary to bilateral symmetric osteosclerosis of metadiaphysis of femur, tibia and fibula+ Bland appearing histiocytes characterized by abundant foamy (xanthomatous) cytoplasm with surrounding fibrosis ([Mod Pathol 2018;31:581](29192649))+ Negative for [OCT2](https://www.pathologyoutlines.com/topic/stainsOCT2.html) and [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html) ([Am J Surg Pathol 2021;45:35](33177341), [Am J Clin Pathol 2023;160:1](37167084))+ Associated with MAPK pathway mutations, with *BRAF* V600E mutated in ~50 - 60% of cases+ Lacks *ALK* gene fusions* [Langerhans cell histiocytosis](https://www.pathologyoutlines.com/topic/lymphnodeslch.html):\n          + Langerhans cells characterized by irregular, grooved, folded or indented nuclei with fine chromatin, inconspicuous nucleoli and abundant pale eosinophilic cytoplasm+ Positive for [S100](https://www.pathologyoutlines.com/topic/stainss100.html), [CD1a](https://www.pathologyoutlines.com/topic/cdmarkerscd1a.html) and [langerin](https://www.pathologyoutlines.com/topic/cdmarkerscd200.html#cd207); negative for [factor XIIIa](https://www.pathologyoutlines.com/topic/stainsfactorxiiia.html) and [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html) ([Am J Clin Pathol 2023;160:1](37167084))+ Lacks *ALK* gene fusions* [Inflammatory myofibroblastic tumor](https://www.pathologyoutlines.com/topic/softtissueinflammyofibro.html) (especially breast and soft tissue tumors):\n            + Proliferation of [ALK](https://www.pathologyoutlines.com/topic/stainsalk.html) positive spindle cells of myofibroblastic origin with variable prominent lymphoplasmacytic infiltrates+ Lesional cells are positive for [vimentin](https://www.pathologyoutlines.com/topic/stainsvimentin.html) (diffuse, strong), [smooth muscle actin](https://www.pathologyoutlines.com/topic/stainsalphasmoothmuscleactin.html), [muscle specific actin](https://www.pathologyoutlines.com/topic/stainsactinmusclespecific.html), [calponin](https://www.pathologyoutlines.com/topic/stainscalponin.html) and [desmin](https://www.pathologyoutlines.com/topic/stainsdesmin.html) (variable)+ [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html) / [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163) positive histiocytes may be present in the background but are not the lesional cells"
  },
  {
    "id": "alk-histiocytosis_46276_1750165655.txt-30",
    "source_document": "alk-histiocytosis_46276_1750165655.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesalkhistiocytosis.html#additionalreferences474612",
    "clean_content": "Additional references\n\n* [WHO Classification of Tumours Editorial Board: Haematolymphoid Tumours, 5th Edition, 2024](https://www.amazon.com/exec/obidos/ASIN/9283245202/pathologyoutl-20), [BMJ Case Rep 2018;2018:bcr2018224506](29514838), [Acta Neuropathol 2019;138:335](31119374), [Neuropathol Appl Neurobiol 2021;47:878](34048085), [Leuk Lymphoma 2021;62:1234](33353436), [J Breast Imaging 2022;4:336](https://doi.org/10.1093/jbi/wbab072), [J Hematopathol 2021;14:89](https://doi.org/10.1007/s12308-021-00443-x), [Hum Pathol Case Rep 2021;24:200504](https://doi.org/10.1016/j.ehpc.2021.200504), [Hum Pathol Case Rep 2020;21:200404](https://doi.org/10.1016/j.ehpc.2020.200404)"
  }
]